NCT03179618

Brief Summary

This study evaluates the clinical efficacy of Xuefu Zhuyu Decoction in the treatment of unstable angina pectoris. All of the patients will be divided into 2 arms randomly. One of the arms will be treated by conventional western medicine, the other one will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jul 2017

Typical duration for phase_4

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 5, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 7, 2017

Completed
24 days until next milestone

Study Start

First participant enrolled

July 1, 2017

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

June 7, 2017

Status Verified

June 1, 2017

Enrollment Period

2.3 years

First QC Date

June 5, 2017

Last Update Submit

June 5, 2017

Conditions

Keywords

Unstable AnginaXuefu Zhuyu Decoction

Outcome Measures

Primary Outcomes (1)

  • Mortality

    Death caused by cardiovascular disease

    Six months after drug intervention

Secondary Outcomes (4)

  • Myocardial enzymes

    At baseline and 4 weeks after drug intervention

  • 3. Blood lipid The unit is mmol/L. Blood lipid

    At baseline and 4 weeks after drug intervention

  • Treadmill exercise test

    At baseline and 4 weeks after drug intervention

  • The incidence of myocardial infarction or heart failure

    Six months after drug intervention

Study Arms (2)

Qi stagnation and blood stasis

EXPERIMENTAL

Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.

Drug: Anti-Platelet DrugsDrug: Lipid Regulating DrugsDrug: Coronary VasodilatorDrug: Xuefu Zhuyu Decoction

Conventional western medicine

OTHER

Patients in this group will be treated by conventional western medicine, including anti-platelet drugss,lipid regulating drugs, coronary vasodilator, etc.

Drug: Anti-Platelet DrugsDrug: Lipid Regulating DrugsDrug: Coronary Vasodilator

Interventions

Including aspirin and clopidogrel, etc.

Conventional western medicineQi stagnation and blood stasis

Mainly including statins

Conventional western medicineQi stagnation and blood stasis

Mainly including nitrates

Conventional western medicineQi stagnation and blood stasis

Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.

Qi stagnation and blood stasis

Eligibility Criteria

Age35 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants diagnosed with coronary heart disease through coronary angiography or coronary CTA;
  • Patients have at least one of these symptoms:
  • The stability of the nature of angina pectoris changes, that is, frequent attacks of angina pectoris, serious degree and prolonged duration;
  • Angina pectoris during rest;
  • The recent occurrence of angina pectoris caused by mild physical activity in the last month.

You may not qualify if:

  • Patients diagnosed with stable angina; Patients with acute myocardial infarction; Chest pain caused by congenital heart disease, valvular heart disease, severe neurosis or arrhythmia; The heart function grade is III or IV; Patients with acute cerebral infarction; Patients complicated with other serious primary diseases; Patients with acute infection in recent 2 weeks; Uncontrolled hypertension (the resting blood pressure \>160/95mmHg within one week); Diabetics emerged with serious diabetic complications; Patients can't finish the questionnaire due to abnormal mental and nervous or mental disorders; Pregnant or lactating women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (5)

  • Yi GZ, Qiu YQ, Xiao Y, Yuan LX. The usefulness of xuefu zhuyu tang for patients with angina pectoris: a meta-analysis and systematic review. Evid Based Complement Alternat Med. 2014;2014:521602. doi: 10.1155/2014/521602. Epub 2014 Aug 31.

  • Qiu Y, Xu H, Shi D. Traditional chinese herbal products for coronary heart disease: an overview of cochrane reviews. Evid Based Complement Alternat Med. 2012;2012:417387. doi: 10.1155/2012/417387. Epub 2012 Mar 28.

  • Liu W, Xiong X, Yang X, Chu F, Liu H. The Effect of Chinese Herbal Medicine Gualouxiebaibanxia Decoction for the Treatment of Angina Pectoris: A Systematic Review. Evid Based Complement Alternat Med. 2016;2016:8565907. doi: 10.1155/2016/8565907. Epub 2016 Sep 29.

  • Wang J, Yang X, Chu F, Chen J, He Q, Yao K, Teng F, Gao Y, Xing Y, Wu A, Xing Y. The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: a randomised controlled clinical trial. Evid Based Complement Alternat Med. 2013;2013:896467. doi: 10.1155/2013/896467. Epub 2013 May 8.

  • Wang J, Yu G. A Systems Biology Approach to Characterize Biomarkers for Blood Stasis Syndrome of Unstable Angina Patients by Integrating MicroRNA and Messenger RNA Expression Profiling. Evid Based Complement Alternat Med. 2013;2013:510208. doi: 10.1155/2013/510208. Epub 2013 May 14.

MeSH Terms

Conditions

Angina, Unstable

Interventions

Lipid Regulating AgentsXue-Fu-Zhu-Yu decoction

Condition Hierarchy (Ancestors)

Angina PectorisMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesChest PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Therapeutic UsesPharmacologic ActionsChemical Actions and Uses

Study Officials

  • Jun Li, MD

    Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Chief Physician

Study Record Dates

First Submitted

June 5, 2017

First Posted

June 7, 2017

Study Start

July 1, 2017

Primary Completion

October 1, 2019

Study Completion

December 1, 2019

Last Updated

June 7, 2017

Record last verified: 2017-06